Journal article icon

Journal article

The Sputnik V moment: biotech, biowarfare and COVID-19 vaccine development in Russia and in former Soviet satellite states

Abstract:
Why has Russia been able to develop and produce Sputnik V while Central and Eastern European (CEE) countries that are members of the European Union have only played a marginal role in global supply chains for the production of vaccines against COVID-19? We argue that this capacity results from efforts by Russia’s national security state and entrepreneurs to turn a Soviet advantage in the development of biological weapons into a contemporary public health advantage in vaccine and drug development. CEE countries have lacked Russia’s historical legacy of and contemporary drive for security motivated statecraft. Nor have they massively invested – as for example Cuba has – into their public health systems and in potential synergies between such systems and biotech firms.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1080/21599165.2022.2121117

Authors


More by this author
Institution:
University of Oxford
Division:
SSD
Department:
Social Policy & Intervention
Oxford college:
Kellogg College
Role:
Author


Publisher:
Taylor and Francis
Journal:
East European Politics More from this journal
Volume:
38
Issue:
4
Pages:
571-593
Publication date:
2022-09-21
Acceptance date:
2022-01-12
DOI:
EISSN:
2159-9173
ISSN:
2159-9165


Language:
English
Keywords:
Pubs id:
1247019
Local pid:
pubs:1247019
Deposit date:
2022-03-24

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP